Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
5094
¥ millions (market capitalization of tradable shares)Wording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedStatements about the use of capital
Payout ratio / DOE policyFor the fiscal year ending March 2027, an ordinary dividend of ¥30 per share and a payout ratio of 43.6%. The company plans to maintain ongoing shareholder returns.The payout ratio is the proportion of profit paid out as dividends, while DOE is the ratio of dividends to net assets.
Self-assessment of PBR and share priceThe company recognizes that the weak share price was the primary factor behind its failure to meet the free-float market capitalization criterion. As of the end of March 2026, free-float market capitalization was ¥5,094 million, below the criterion of ¥10,000 million.PBR is a measure of how many times the share price is the book value per share.
Key initiatives
01Accelerate growth in the Medical Platform Business
02Enter and expand the dental distribution business
03Stable shareholder returns
04Strengthening IR activities
Plan assumptionsThe earnings forecast for the fiscal year ending March 2027 is based on growth in MedicalDOC page views, enhancement of content and improvement in service value. Quantified assumptions: not disclosed.
Segment targetSegment name Medical Platform Business / Sales Target ¥7,000 million for the fiscal year ending March 2027 (up ¥1,965 million year on year, or 39.0%) / Profit Target Not disclosed
Risks identified by the company
If compliance with the free-float market capitalization criterion cannot be confirmed during the improvement period through 31 March 2027, the company may be designated a Security Under Supervision (Confirmation Pending).
If compliance is still not confirmed in the subsequent review, the company may be designated a Security to Be Delisted and delisted on 1 October 2027.
The possibility that compliance with the Prime Market listing maintenance criteria may become difficult due to changes in the business environment and other factors.
| Item | Details |
|---|---|
| Plan name | Plan to Meet Listing Maintenance Criteria (Entering Improvement Period) |
| Plan period | End of March 2027 |
| Progress against the plan | Formulated |
| Payout ratio / DOE policy | For the fiscal year ending March 2027, an ordinary dividend of ¥30 per share and a payout ratio of 43.6%. The company plans to maintain ongoing shareholder returns. |
| Self-assessment of PBR and share price | The company recognizes that the weak share price was the primary factor behind its failure to meet the free-float market capitalization criterion. As of the end of March 2026, free-float market capitalization was ¥5,094 million, below the criterion of ¥10,000 million. |
| Segment target | Segment name Medical Platform Business / Sales Target ¥7,000 million for the fiscal year ending March 2027 (up ¥1,965 million year on year, or 39.0%) / Profit Target Not disclosed |
| Plan assumptions | The earnings forecast for the fiscal year ending March 2027 is based on growth in MedicalDOC page views, enhancement of content and improvement in service value. Quantified assumptions: not disclosed. |
| Key initiatives | Accelerate growth in the Medical Platform Business, Enter and expand the dental distribution business, Stable shareholder returns, Strengthening IR activities |
| Risks identified | If compliance with the free-float market capitalization criterion cannot be confirmed during the improvement period through 31 March 2027, the company may be designated a Security Under Supervision (Confirmation Pending)., If compliance is still not confirmed in the subsequent review, the company may be designated a Security to Be Delisted and delisted on 1 October 2027., The possibility that compliance with the Prime Market listing maintenance criteria may become difficult due to changes in the business environment and other factors. |
| Publication date | 19 June 2026 |
Items this document does not state (15)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetTreasury share acquisition policyCost of capitalTotal investment planInvestment amount by sectorNon-financial targetsResults under the previous planReason for revision or withdrawalSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company stated that, although its free-float ratio exceeds the criterion, the primary reason for non-compliance is the low market capitalization resulting from the weak share price. It also stated that the decline in operating profit resulted from upfront investments in new businesses, personnel recruitment and sales promotion, and that profitability fell below market expectations.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.